The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro

[1]  V. Hasselblad,et al.  Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. , 2004, JAMA.

[2]  R. Califf,et al.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.

[3]  L. Newby,et al.  1077-71 The association between care and outcomes in patients with acute coronary syndrome: National results from CRUSADE , 2004 .

[4]  E. Vicaut,et al.  Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. , 2004, Journal of the American College of Cardiology.

[5]  A. Kastrati,et al.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. , 2004, The New England journal of medicine.

[6]  W. Gibler,et al.  A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. , 2003, American heart journal.

[7]  E. Peterson,et al.  Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. , 2003, Journal of the American College of Cardiology.

[8]  P. Armstrong,et al.  Meta-analysis of the efficacy and safety of unfractionated heparin versus enoxaparin in conjunction with tenecteplase for ST elevation myocardial infarction: Insights from ASSENT 3 and ASSENT 3 PLUS , 2003 .

[9]  J. Ioannidis,et al.  Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. , 2003, Journal of the American College of Cardiology.

[10]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.

[11]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[12]  K. Harre,et al.  Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). , 2002, Journal of the American College of Cardiology.

[13]  M L Simoons,et al.  A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.

[14]  W Klein,et al.  Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). , 2002, European heart journal.

[15]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[16]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.

[17]  R. Califf,et al.  Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). , 2001, The American journal of cardiology.

[18]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[19]  E. Topol,et al.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.

[20]  R. Giugliano,et al.  Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. , 2000, The American journal of cardiology.

[21]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[22]  A. Adgey,et al.  Management of acute coronary syndromes , 2000, BMJ : British Medical Journal.

[23]  J. Graham-Pole,et al.  Phase II Trial , 1994, Annals of Internal Medicine.

[24]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[25]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.